FucT-IX Activators
Fucosyltransferase IX Activators, often referred to as FucT-IX Activators, belong to a specific chemical class that plays a crucial role in the modification of glycoproteins and glycolipids. Fucosyltransferases are a family of enzymes responsible for transferring fucose molecules onto various glycoconjugates, thereby influencing their structural and functional properties. FucT-IX Activators are compounds designed to enhance the activity of Fucosyltransferase IX, a specific member of this enzyme family.
Fucosylation is a post-translational modification that involves the addition of fucose sugars to glycoproteins and glycolipids. This process is essential for numerous cellular functions, including cell-cell adhesion, immune response regulation, and signal transduction. Fucosyltransferase IX, when activated by FucT-IX Activators, catalyzes the transfer of fucose residues to specific target molecules. This modification can profoundly impact the binding affinity of glycoproteins to their ligands, influencing cell adhesion and signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin, as an antibiotic, directly impacts FucT-IX and related pathways by inhibiting N-linked glycosylation. This inhibition, blocking the formation of essential sugar intermediates, can indirectly increase the activity of FucT-IX, which relies on glycosylation for its function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine, a natural alkaloid, indirectly increases the activity of FucT-IX and related pathways by inhibiting α-mannosidase II. This inhibition can lead to the accumulation of high-mannose-type N-glycans, potentially affecting glycosylation processes, including those involving FucT-IX. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxyglucose (2-DG), a glucose analog, indirectly activating FucT-IX and related pathways by competing with glucose in glycolysis. This competition can reduce the availability of glycosylation substrates, potentially affecting glycosylation, including fucosylation, which relies on sugar nucleotide donors. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine indirectly influences FucT-IX and related pathways by inhibiting α-mannosidase I. This inhibition can disrupt early glycosylation processing, potentially activating glycosylation pathways that contribute to the activity of of FucT-IX. | ||||||